Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rapid in vitro evolution of flucytosine resistance in Candida auris

ABSTRACT: Rapid in vitro evolution of flucytosine resistance in Candida auris

PROVIDER: PRJNA1139166 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29929700_1.fastq.gz	Fastqsanger.gz
	SRR29929700_2.fastq.gz	Fastqsanger.gz
	SRR29929701_1.fastq.gz	Fastqsanger.gz
	SRR29929701_2.fastq.gz	Fastqsanger.gz
	SRR29929702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Rapid in vitro evolution of flucytosine resistance in Candida auris

Project description:Comparative transcriptomic profiling of Candida auris derivative clones collected from 5FC-containing medium in comparison to the Wild-Type Strain

2024-08-22 | GSE272878 | GEO

Haploid and Deploid for Candida auris

Project description:The expression difference for haploid and deploid of Candida auris

2020-09-13 | GSE149284 | GEO

Transcriptional Signatures Predict Phenotypic Variations of Candida auris

Project description:Transcriptomic analysis of different Candida auris clinical isolates with distinct antifungal susceptibility profiles.

2021-01-30 | GSE165762 | GEO

Candida auris whole cell proteomics

Project description:Whole cell proteomics of Candida auris MMC1 and MMC2 strains.

2019-05-24 | PXD013456 | Pride

Candida auris extracellular vesicle proteomics

Project description:Proteomic analysis of extracellular vesicles from Candida auris MMC1 and MMC2 strains.

2021-11-12 | PXD026768 | Pride

Transcriptomics and phenotyping define signatures associated with echinocandin resistance in Candida auris

Project description:Transcriptomic analysis of different Candida auris clinical isolates

2022-03-16 | GSE198410 | GEO

Candida auris infection of human whole blood

Project description:To mimic the initial phases of systemic Candida infections with dissemination via the bloodstream, we used an ex vivo whole blood infection model. Dual TP of C. auris in blood gave insights into fungal adaptations and survival mechanisms as well as the host response to the infection.

2022-01-12 | GSE179000 | GEO

Transcriptome analysis of tebuconazole adaptors in Candida auris

Project description:Candida auris wild type strain FY279 was used to tebuconazole adaptors. Transcriptomes of two adaptors, TJ42 and TJ44, were compared to wild type.

2023-09-05 | E-MTAB-13215 | biostudies-arrayexpress

Transcriptome analysis of Candida auris response to tunicamycin

Project description:Candida auris reference strain B11221 was exposed to sub-inhibitory (1μg/ml) and inhibitory (8μg/ml) tunicamycin for 3h. Transcriptomes were compared to no drug treatment control.

2023-12-23 | E-MTAB-12667 | biostudies-arrayexpress

Overcoming amphotericin B resistance in Candida auris using the antiemetic drug, rolapitant

Project description:The emergence of Candida auris poses a significant health challenge that has led to a new era of multidrug-resistant fungal infections. Invasive infections caused by C. auris are usually associated with remarkable morbidity and mortality. For many years, amphotericin B (AmB) remained the most efficient and the last line of treatment against most hard-to-treat fungal infections. However, strains of C. auris possess extraordinary resistance to most antifungal agents, including AmB. In this study, we screened ~2600 FDA-approved drugs and clinical compounds to identify the antiemetic drug rolapitant as a promising enhancer to AmB against C. auris. Rolapitant exhibited potent synergistic interactions with AmB against all tested (29/29) C. auris isolates. In a time-kill assay, rolapitant restored the fungicidal activity of AmB within 4 h. Additionally, the synergistic relationship between rolapitant and AmB was observed against other medically crucial Candida, Cryptococcus and Aspergillus species with ΣFICI that ranged from 0.16 to 0.5. In a transcriptomic study, ion transporters and ATP generation were identified as primary pathways impacted in C. auris AR0390 cells exposed to rolapitant. An ATP luminescence assay confirmed that rolapitant, at sub-inhibitory concentrations, significantly interfered with ATP production in C. auris. Moreover, rolapitant enhanced the in vivo activity of AmB in a mouse model of disseminated C. auris infection, as the combination reduced the fungal burden in murine kidneys by ~1 log (~90%) colony forming units. Our findings warrant further investigation of using rolapitant to overcome AmB resistance in C. auris and other fungal species.

2024-09-26 | GSE263806 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data